Slide Insurance Holdings enters its July 28 earnings date with an unusual tension: the stock is up 7% on the week and 24% over the past month, yet Morgan Stanley just cut its rating to Equal-Weight — a direct vote of caution from one of the Street's bellwether names against a backdrop of genuine price momentum.
The Street picture is mixed enough to warrant attention. Morgan Stanley's Bob Huang downgraded SLDE to Equal-Weight on July 6, trimming his target to $20 from $23 — essentially in line with where the stock closed Tuesday at $20.78. That single move pulls against the rest of the coverage universe: Keefe, Bruyette & Woods raised its target to $24 this week while holding Outperform, and Barclays trimmed its own target to $27 from $31 while staying Overweight. The consensus remains a buy, with four Outperform/Overweight ratings against one Hold, and a mean target of $23.80 — roughly 14% above current levels. The bull case rests on an 89% CAGR in gross premiums written from 2022–2024 and Florida legislative tailwinds; the bear case centres on reinsurance cost exposure and catastrophic event risk in coastal markets. The Morgan Stanley downgrade cuts through the noise: the stock's rapid re-rating has likely pulled forward much of the near-term fundamental upside.
Positioning tells a calmer story. Short interest has been declining steadily — down about 15% over the past month to 4.2% of float, the lowest level in the 30-day window. Borrow conditions are exceptionally loose: availability runs at roughly 720%, meaning the lending pool holds more than seven shares available for every one already borrowed. Cost to borrow is minimal at 0.47%, down nearly 19% on the week. The ORTEX short score has drifted lower, from around 54 in late June to 51 today — a middling reading that points to no short-side conviction building. Options lean slightly bullish relative to recent norms: the put/call ratio is 0.53, modestly below its 20-day average of 0.62, though the z-score of -0.48 flags this as well within normal range. Overall, positioning looks relaxed rather than charged in either direction.
Institutional ownership adds one noteworthy data point. BlackRock added roughly 2.5 million shares in the most recent reported period, bringing its stake to 6.7% — a meaningful accumulation for a stock of SLDE's size. Vanguard and Arrowstreet both established or substantially expanded positions as of March 31. On the insider side, the picture is less clean: the CEO and COO each sold a small tranche on June 30 following routine award grants, and a director, Andrew Wright, sold a combined 61,000 shares across three transactions in late June. None of these are large relative to total holdings, but the selling cluster from multiple insiders into the recent price rally is worth noting ahead of earnings.
The earnings history offers limited guidance — recent post-print moves have been small, ranging from flat to down roughly 3% over the following five days. The next report drops July 28. With the stock up 24% in a month, Morgan Stanley's new target sitting at the current price, and Barclays trimming despite holding its Overweight, the key question into that print is whether SLDE's premium growth trajectory and reinsurance economics justify the multiple re-rating the market has already delivered.
See the live data behind this article on ORTEX.
Open SLDE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
